Actively Recruiting
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Led by Novartis Pharmaceuticals · Updated on 2026-05-12
272
Participants Needed
16
Research Sites
180 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
CONDITIONS
Official Title
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female participants 50 years of age or older
- Diagnosis of geographic atrophy secondary to age-related macular degeneration in at least one eye
- Total geographic atrophy area between 2.5 and 17.5 mm2
- If lesions are multifocal, total area must be between 2.5 and 17.5 mm2 with at least one lesion of 1.25 mm2 or larger
- Entire geographic atrophy lesion must be visible on a macula-centered image and not connected to peripapillary atrophy
- Best corrected visual acuity of at least 35 letters (20/200) in the study eye
You will not qualify if you...
- History or current presence of choroidal neovascularization in either eye
- Previous cell or gene therapy in either eye
- Macular atrophy caused by conditions other than age-related macular degeneration
- Intraocular surgery in the study eye within 3 months before baseline
- Significant media opacity, eye movement disorders, severe ptosis, extraocular motility restriction, or head tremor that would interfere with eye imaging
- Other protocol-defined exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 16 locations
1
Salehi Retina Institute
Huntington Beach, California, United States, 92647
Actively Recruiting
2
Retinal Consultants Medical Group Inc
Sacramento, California, United States, 95841
Actively Recruiting
3
Advanced Research LLC
Boynton Beach, Florida, United States, 33437
Actively Recruiting
4
Advanced Research LLC
Deerfield Beach, Florida, United States, 33064
Actively Recruiting
5
Retina Vitreous Associates of Florida
St. Petersburg, Florida, United States, 33711
Actively Recruiting
6
Opthamalic Consultants of Boston
Boston, Massachusetts, United States, 02114
Actively Recruiting
7
NJ Retina
Toms River, New Jersey, United States, 08755
Actively Recruiting
8
Erie Retina Research LLC
Erie, Pennsylvania, United States, 16505
Actively Recruiting
9
Retina Consultants TX Rsrch Ctr
Bellaire, Texas, United States, 77401
Actively Recruiting
10
Retina Consultants of Houston PA
Houston, Texas, United States, 77030
Actively Recruiting
11
Retina Consultants of Texas
Katy, Texas, United States, 77494
Actively Recruiting
12
Novartis Investigative Site
Albury, New South Wales, Australia, 2640
Actively Recruiting
13
Novartis Investigative Site
Parramatta, New South Wales, Australia, 2150
Actively Recruiting
14
Novartis Investigative Site
Strathfield, New South Wales, Australia, 2135
Actively Recruiting
15
Novartis Investigative Site
East Melbourne, Victoria, Australia, 3002
Actively Recruiting
16
Novartis Investigative Site
Ottawa, Ontario, Canada, K2B 7E9
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here